Clinical trials
Completed Phase 4 trials in Iran
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
88 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 3 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 9 |
| 2008 | 9 |
| 2009 | 7 |
| 2010 | 7 |
| 2011 | 12 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 88 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tehran University of Medical Sciences | 26 |
| Shiraz University of Medical Sciences | 8 |
| Isfahan University of Medical Sciences | 6 |
| Shahid Beheshti University of Medical Sciences | 6 |
| Baqiyatallah Medical Sciences University | 5 |
| Hormozgan University of Medical Sciences | 3 |
| Royan Institute | 3 |
| Birjand University of Medical Sciences | 2 |
| Mazandaran University of Medical Sciences | 2 |
| Nasim Tabrizi | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 6 |
| Hepatitis C | 6 |
| Cardiovascular Diseases | 5 |
| Diabetes Mellitus | 5 |
| Infertility | 4 |
| Pain | 4 |
| Epilepsy | 3 |
| Hypertension | 3 |
| Acute Pain | 2 |
| Agnosia | 2 |
Trials
Showing 1 to 25 of 88. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.